The Study
Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression
This study looked at mice that got fat and then gave them a medicine to see what changed in their hearts. It found some clues about how the medicine might help, but it didn't prove the medicine caused the changes — it just saw them happen together.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
A drug called semaglutide, used for diabetes and weight loss, was given to obese mice to see if it helped their hearts. Scientists found it lowered harmful chemicals and turned down genes in immune cells called neutrophils that were causing heart inflammation.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 512 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1These changes suggest the drug may help prevent heart damage caused by obesity, but it’s only been tested in mice so far.
- 2Semaglutide lowered TNF-α, IL-6, ROS, and MDA in the heart and blood, and reduced expression of Cxcl2, S100a8, and S100a9 genes in neutrophils.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Molecular and Cellular Biochemistry
Year
2023
Authors
Xiaoyu Pan, Lin Yang, Shuqi Wang, Yanhui Liu, Lin Yue, Shuchun Chen
Related Content
Claims (5)
In mice with obesity, the drug semaglutide is linked to lower levels of certain biological markers that indicate inflammation and oxidative stress in the blood and heart tissue.
In mice with obesity, the drug semaglutide is linked to lower activity of certain genes in heart tissue that are related to neutrophils, a type of immune cell.
In mice with obesity, a medication called semaglutide is linked to weight loss, and this weight loss may be related to lower levels of inflammation and oxidative stress in the heart.
In mice with obesity, a type of immune cell called neutrophils in the heart show increased activity of specific genes linked to inflammation, which may be related to heart stress caused by obesity.
In mice with obesity, the drug semaglutide is linked to lower activity of specific genes produced by neutrophils that are normally increased during obesity, which may help reduce inflammation in the heart.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.